computer program phoenix winnonlin version 8 1 (Certara L.P)
86
Structured Review
Certara L.P
computer program phoenix winnonlin version 8 1
Computer Program Phoenix Winnonlin Version 8 1, supplied by Certara L.P, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+software+program/phoenix+winnonlin/pmc12771343-158-6-12
Average 86 stars, based on 1 article reviews
Computer Program Phoenix Winnonlin Version 8 1, supplied by Certara L.P, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+software+program/phoenix+winnonlin/pmc12771343-158-6-12
Average 86 stars, based on 1 article reviews
computer program phoenix winnonlin version 8 1 - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Software:Article Title: Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof Article Snippet: .. Pharmacokinetic parameters, including the AUC, apparent total body clearance (CL), elimination rate constant (K), half-life (t1⁄2), and relative bioavailability, were analyzed by Article Title: Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism Article Snippet: .. The PK analysis was conducted by Fortrea using Article Title: Oral Poly(N-oxide) zwitterionic nanoplatform for Gambogenic Acid Enhances Mucosal penetration for potentiated anti-angiogenic therapy Article Snippet: .. The pharmacokinetic parameters, including the area under the concentration-time curve (AUC), peak concentration (C max ), and elimination half-life (t 1/2 ), were calculated using a non-compartmental analysis (NCA) model with Analysis:Article Title: Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism Article Snippet: .. The PK analysis was conducted using Article Title: Oral Poly(N-oxide) zwitterionic nanoplatform for Gambogenic Acid Enhances Mucosal penetration for potentiated anti-angiogenic therapy Article Snippet: .. The pharmacokinetic parameters, including the area under the concentration-time curve (AUC), peak concentration (C max ), and elimination half-life (t 1/2 ), were calculated using a non-compartmental analysis (NCA) model with Concentration Assay:Article Title: Oral Poly(N-oxide) zwitterionic nanoplatform for Gambogenic Acid Enhances Mucosal penetration for potentiated anti-angiogenic therapy Article Snippet: .. The pharmacokinetic parameters, including the area under the concentration-time curve (AUC), peak concentration (C max ), and elimination half-life (t 1/2 ), were calculated using a non-compartmental analysis (NCA) model with |